{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T15:28:51Z","timestamp":1789831731589,"version":"4.0.1"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,11,23]],"date-time":"2018-11-23T00:00:00Z","timestamp":1542931200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100015639","name":"Japan Cardiovascular Research Foundation","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100015639","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Drugs Ther"],"published-print":{"date-parts":[[2019,2]]},"DOI":"10.1007\/s10557-018-6839-1","type":"journal-article","created":{"date-parts":[[2018,11,23]],"date-time":"2018-11-23T00:25:49Z","timestamp":1542932749000},"page":"97-103","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":30,"title":["Rationale, Design, and Baseline Characteristics of the Prospective Japan Acute Myocardial Infarction Registry (JAMIR)"],"prefix":"10.1007","volume":"33","author":[{"name":"on behalf of the JAMIR investigators","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Honda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kensaku","family":"Nishihira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunao","family":"Kojima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Misa","family":"Takegami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuhide","family":"Asaumi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makoto","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masami","family":"Kosuge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuhiko","family":"Sakata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morimasa","family":"Takayama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuya","family":"Sumiyoshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hisao","family":"Ogawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuo","family":"Kimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Yasuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,11,23]]},"reference":[{"issue":"25","key":"6839_CR1","doi-asserted-by":"publisher","first-page":"2725","DOI":"10.1161\/CIRCULATIONAHA.107.750117","volume":"118","author":"H Iso","year":"2008","unstructured":"Iso H. Changes in coronary heart disease risk among Japanese. Circulation. 2008;118(25):2725\u20139.","journal-title":"Circulation"},{"issue":"7","key":"6839_CR2","doi-asserted-by":"publisher","first-page":"1646","DOI":"10.1253\/circj.CJ-13-0702","volume":"77","author":"T Ohira","year":"2013","unstructured":"Ohira T, Iso H. Cardiovascular disease epidemiology in Asia: an overview. Circ J. 2013;77(7):1646\u201352.","journal-title":"Circ J"},{"issue":"2","key":"6839_CR3","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1093\/eurheartj\/ehx393","volume":"39","author":"B Ibanez","year":"2018","unstructured":"Ibanez B, James S, Agewall S, Antunes MJ, Bucciarelli-Ducci C, Bueno H, et al. 2017 ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: the task force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J. 2018;39(2):119\u201377.","journal-title":"Eur Heart J"},{"issue":"1","key":"6839_CR4","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1253\/circj.CJ-66-0053","volume":"77","author":"Group JCSJW","year":"2013","unstructured":"Group JCSJW. Guidelines for secondary prevention of myocardial infarction (JCS 2011). Circ J. 2013;77(1):231\u201348.","journal-title":"Circ J"},{"issue":"2","key":"6839_CR5","doi-asserted-by":"publisher","first-page":"83","DOI":"10.5551\/jat.6866","volume":"18","author":"H Iso","year":"2011","unstructured":"Iso H. Lifestyle and cardiovascular disease in Japan. J Atheroscler Thromb. 2011;18(2):83\u20138.","journal-title":"J Atheroscler Thromb"},{"key":"6839_CR6","first-page":"1","volume":"20","author":"S Kojima","year":"2018","unstructured":"Kojima S, Nishihira K, Takegami M, Nakao YM, Honda S, Takahashi J, et al. Nationwide real-world database of 20,462 patients enrolled in the Japanese Acute Myocardial Infarction Registry (JAMIR): impact of emergency coronary intervention in a super-aging population. Int J Cardiol Heart Vasc. 2018;20:1\u20136.","journal-title":"Int J Cardiol Heart Vasc"},{"issue":"12A","key":"6839_CR7","doi-asserted-by":"publisher","first-page":"3H","DOI":"10.1016\/S0002-9149(03)00428-4","volume":"91","author":"AP Selwyn","year":"2003","unstructured":"Selwyn AP. Prothrombotic and antithrombotic pathways in acute coronary syndromes. Am J Cardiol. 2003;91(12A):3H\u201311H.","journal-title":"Am J Cardiol"},{"issue":"4","key":"6839_CR8","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1253\/circj.CJ-09-0982","volume":"74","author":"DJ Angiolillo","year":"2010","unstructured":"Angiolillo DJ, Ueno M, Goto S. Basic principles of platelet biology and clinical implications. Circ J. 2010;74(4):597\u2013607.","journal-title":"Circ J"},{"issue":"14","key":"6839_CR9","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.1016\/j.jacc.2006.11.044","volume":"49","author":"DJ Angiolillo","year":"2007","unstructured":"Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, Alfonso F, Macaya C, Bass TA, et al. Variability in individual responsiveness to clopidogrel: clinical implications, management, and future perspectives. J Am Coll Cardiol. 2007;49(14):1505\u201316.","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"6839_CR10","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1136\/hrt.2011.227272","volume":"98","author":"IY Oh","year":"2012","unstructured":"Oh IY, Park KW, Kang SH, Park JJ, Na SH, Kang HJ, et al. Association of cytochrome P450 2C19*2 polymorphism with clopidogrel response variability and cardiovascular events in Koreans treated with drug-eluting stents. Heart. 2012;98(2):139\u201344.","journal-title":"Heart"},{"issue":"8","key":"6839_CR11","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1177\/0091270009355161","volume":"50","author":"M Man","year":"2010","unstructured":"Man M, Farmen M, Dumaual C, Teng CH, Moser B, Irie S, et al. Genetic variation in metabolizing enzyme and transporter genes: comprehensive assessment in 3 major East Asian subpopulations with comparison to Caucasians and Africans. J Clin Pharmacol. 2010;50(8):929\u201340.","journal-title":"J Clin Pharmacol"},{"issue":"8","key":"6839_CR12","doi-asserted-by":"publisher","first-page":"1498","DOI":"10.1253\/circj.CJ-09-0019","volume":"73","author":"T Jinnai","year":"2009","unstructured":"Jinnai T, Horiuchi H, Makiyama T, Tazaki J, Tada T, Akao M, et al. Impact of CYP2C19 polymorphisms on the antiplatelet effect of clopidogrel in an actual clinical setting in Japan. Circ J. 2009;73(8):1498\u2013503.","journal-title":"Circ J"},{"issue":"10","key":"6839_CR13","doi-asserted-by":"publisher","first-page":"1166","DOI":"10.1093\/eurheartj\/ehi877","volume":"27","author":"T Jernberg","year":"2006","unstructured":"Jernberg T, Payne CD, Winters KJ, Darstein C, Brandt JT, Jakubowski JA, et al. Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin-treated patients with stable coronary artery disease. Eur Heart J. 2006;27(10):1166\u201373.","journal-title":"Eur Heart J"},{"issue":"3","key":"6839_CR14","first-page":"589","volume":"112","author":"PA Gurbel","year":"2014","unstructured":"Gurbel PA, Bergmeijer TO, Tantry US, et al. The effect of CYP2C19 gene polymorphisms on the pharmacokinetics and pharmacodynamics of prasugrel 5-mg, prasugrel 10-mg and clopidogrel 75-mg in patients with coronary artery disease. Thromb Haemost. 2014;112(3):589\u201397.","journal-title":"Thromb Haemost"},{"issue":"20","key":"6839_CR15","doi-asserted-by":"publisher","first-page":"2001","DOI":"10.1056\/NEJMoa0706482","volume":"357","author":"SD Wiviott","year":"2007","unstructured":"Wiviott SD, Braunwald E, McCabe CH, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2007;357(20):2001\u201315.","journal-title":"N Engl J Med"},{"issue":"4","key":"6839_CR16","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1056\/NEJMoa0809171","volume":"360","author":"JL Mega","year":"2009","unstructured":"Mega JL, Close SL, Wiviott SD, Shen L, Hockett RD, Brandt JT, et al. Cytochrome p-450 polymorphisms and response to clopidogrel. N Engl J Med. 2009;360(4):354\u201362.","journal-title":"N Engl J Med"},{"issue":"19","key":"6839_CR17","doi-asserted-by":"publisher","first-page":"2553","DOI":"10.1161\/CIRCULATIONAHA.109.851949","volume":"119","author":"JL Mega","year":"2009","unstructured":"Mega JL, Close SL, Wiviott SD, Shen L, Hockett RD, Brandt JT, et al. Cytochrome P450 genetic polymorphisms and the response to prasugrel: relationship to pharmacokinetic, pharmacodynamic, and clinical outcomes. Circulation. 2009;119(19):2553\u201360.","journal-title":"Circulation"},{"issue":"10","key":"6839_CR18","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1038\/nrcardio.2014.104","volume":"11","author":"GN Levine","year":"2014","unstructured":"Levine GN, Jeong YH, Goto S, Anderson JL, Huo Y, Mega JL, et al. Expert consensus document: World Heart Federation expert consensus statement on antiplatelet therapy in East Asian patients with ACS or undergoing PCI. Nat Rev Cardiol. 2014;11(10):597\u2013606.","journal-title":"Nat Rev Cardiol"},{"issue":"8","key":"6839_CR19","doi-asserted-by":"publisher","first-page":"1923","DOI":"10.1253\/circj.CJ-13-0786","volume":"77","author":"J Hata","year":"2013","unstructured":"Hata J, Kiyohara Y. Epidemiology of stroke and coronary artery disease in Asia. Circ J. 2013;77(8):1923\u201332.","journal-title":"Circ J"},{"issue":"1","key":"6839_CR20","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1161\/01.STR.19.1.48","volume":"19","author":"K Ueda","year":"1988","unstructured":"Ueda K, Hasuo Y, Kiyohara Y, Wada J, Kawano H, Kato I, et al. Intracerebral hemorrhage in a Japanese community, Hisayama: incidence, changing pattern during long-term follow-up, and related factors. Stroke. 1988;19(1):48\u201352.","journal-title":"Stroke"},{"issue":"2","key":"6839_CR21","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1007\/s12928-017-0459-8","volume":"33","author":"M Nakamura","year":"2018","unstructured":"Nakamura M, Iizuka T, Sagawa K, Abe K, Chikada S, Arai M. Prasugrel for Japanese patients with acute coronary syndrome in short-term clinical practice (PRASFIT-Practice I): a postmarketing observational study. Cardiovasc Interv Ther. 2018;33(2):135\u201345.","journal-title":"Cardiovasc Interv Ther"},{"issue":"16","key":"6839_CR22","doi-asserted-by":"publisher","first-page":"2020","DOI":"10.1161\/CIR.0b013e31826e1058","volume":"126","author":"K Thygesen","year":"2012","unstructured":"Thygesen K, Alpert JS, Jaffe AS, Simoons ML, Chaitman BR, White HD. Third universal definition of myocardial infarction. Circulation. 2012;126(16):2020\u201335.","journal-title":"Circulation"},{"issue":"1","key":"6839_CR23","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1161\/01.CIR.90.1.583","volume":"90","author":"H Tunstall-Pedoe","year":"1994","unstructured":"Tunstall-Pedoe H, Kuulasmaa K, Amouyel P, Arveiler D, Rajakangas AM, Pajak A. Myocardial infarction and coronary deaths in the World Health Organization MONICA Project. Registration procedures, event rates, and case-fatality rates in 38 populations from 21 countries in four continents. Circulation. 1994;90(1):583\u2013612.","journal-title":"Circulation"},{"key":"6839_CR24","unstructured":"Kimura K, Asai T, Ogawa H et al. Guidelines for the management of patients with ST-elevation acute myocardial infarction (JCS 2013), article in Japanese, \n                    http:\/\/www.j-circ.or.jp\/guideline\/pdf\/JCS2013_kimura_d.pdf"},{"key":"6839_CR25","unstructured":"Kimura T, Issiki T, Ohno T et al. Guidelines for management of acute coronary syndrome without persistent ST segment elevation (JCS 2012), article in Japanese, \n                    http:\/\/www.j-circ.or.jp\/guideline\/pdf\/JCS2012_kimura_d.pdf"},{"issue":"4","key":"6839_CR26","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1016\/j.ahj.2006.04.012","volume":"152","author":"SD Wiviott","year":"2006","unstructured":"Wiviott SD, Antman EM, Gibson CM, Montalescot G, Riesmeyer J, Weerakkody G, et al. Evaluation of prasugrel compared with clopidogrel in patients with acute coronary syndromes: design and rationale for the TRial to assess Improvement in Therapeutic Outcomes by optimizing platelet InhibitioN with prasugrel Thrombolysis In Myocardial Infarction 38 (TRITON-TIMI 38). Am Heart J. 2006;152(4):627\u201335.","journal-title":"Am Heart J"},{"issue":"7","key":"6839_CR27","doi-asserted-by":"publisher","first-page":"2114","DOI":"10.1016\/S0735-1097(01)01702-8","volume":"38","author":"CP Cannon","year":"2001","unstructured":"Cannon CP, Battler A, Brindis RG, et al. American College of Cardiology key data elements and definitions for measuring the clinical management and outcomes of patients with acute coronary syndromes. A report of the American College of Cardiology Task Force on Clinical Data Standards (Acute Coronary Syndromes Writing Committee). J Am Coll Cardiol. 2001;38(7):2114\u201330.","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"6839_CR28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/0735-1097(88)90158-1","volume":"11","author":"AK Rao","year":"1988","unstructured":"Rao AK, Pratt C, Berke A, Jaffe A, Ockene I, Schreiber TL, et al. Thrombolysis in Myocardial Infarction (TIMI) Trial\u2014phase I: hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinase. J Am Coll Cardiol. 1988;11(1):1\u201311.","journal-title":"J Am Coll Cardiol"},{"issue":"23","key":"6839_CR29","doi-asserted-by":"publisher","first-page":"2736","DOI":"10.1161\/CIRCULATIONAHA.110.009449","volume":"123","author":"R Mehran","year":"2011","unstructured":"Mehran R, Rao SV, Bhatt DL, Gibson CM, Caixeta A, Eikelboom J, et al. Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium. Circulation. 2011;123(23):2736\u201347.","journal-title":"Circulation"},{"issue":"17","key":"6839_CR30","doi-asserted-by":"publisher","first-page":"2344","DOI":"10.1161\/CIRCULATIONAHA.106.685313","volume":"115","author":"DE Cutlip","year":"2007","unstructured":"Cutlip DE, Windecker S, Mehran R, Boam A, Cohen DJ, van Es GA, et al. Clinical end points in coronary stent trials: a case for standardized definitions. Circulation. 2007;115(17):2344\u201351.","journal-title":"Circulation"},{"issue":"4","key":"6839_CR31","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1253\/circj.CJ-13-0174","volume":"77","author":"H Daida","year":"2013","unstructured":"Daida H, Miyauchi K, Ogawa H, Yokoi H, Matsumoto M, Kitakaze M, et al. Management and two-year long-term clinical outcome of acute coronary syndrome in Japan: prevention of atherothrombotic incidents following ischemic coronary attack (PACIFIC) registry. Circ J. 2013;77(4):934\u201343.","journal-title":"Circ J"},{"issue":"3","key":"6839_CR32","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1055\/s-0038-1626697","volume":"118","author":"J Kang","year":"2018","unstructured":"Kang J, Han JK, Ahn Y, Chae SC, Kim YJ, Chae IH, et al. Third-generation P2Y12 inhibitors in East Asian acute myocardial infarction patients: a nationwide prospective multicentre study. Thromb Haemost. 2018;118(3):591\u2013600.","journal-title":"Thromb Haemost"},{"key":"6839_CR33","doi-asserted-by":"publisher","first-page":"1866","DOI":"10.1253\/circj.CJ-18-0112","volume":"82","author":"MC Kim","year":"2018","unstructured":"Kim MC, Jeong MH, Sim DS, Hong YJ, Kim JH, Ahn Y, et al. Comparison of clinical outcomes between ticagrelor and prasugrel in patients with ST-segment elevation myocardial infarction\u2014results from the Korea Acute Myocardial Infarction Registry-National Institutes of Health. Circ J. 2018;82:1866\u201373.","journal-title":"Circ J"},{"key":"6839_CR34","doi-asserted-by":"crossref","unstructured":"Myocardial infarction redefined\u2014a consensus document of the Joint European Society of Cardiology\/American College of Cardiology Committee for the redefinition of myocardial infarction. Eur Heart J. 2000;21(18):1502\u201313.","DOI":"10.1053\/euhj.2000.2305"}],"container-title":["Cardiovascular Drugs and Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10557-018-6839-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10557-018-6839-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10557-018-6839-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,20]],"date-time":"2020-05-20T09:06:22Z","timestamp":1589965582000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10557-018-6839-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11,23]]},"references-count":34,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,2]]}},"alternative-id":["6839"],"URL":"https:\/\/doi.org\/10.1007\/s10557-018-6839-1","relation":{},"ISSN":["0920-3206","1573-7241"],"issn-type":[{"value":"0920-3206","type":"print"},{"value":"1573-7241","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,11,23]]},"assertion":[{"value":"23 November 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"Dr. Yasuda reports remuneration for lectures from Takeda, Daiichi Sankyo, and Bristol-Myers Squibb and trust research\/joint research funds from Takeda and Daiichi Sankyo; Dr. Takayama reports lecture fees from Daiichi Sankyo; and Dr. Ogawa reports lecture fees and research grants from AstraZeneca, Bayer, Boehringer Ingelheim,Daiichi Sankyo, Pfizer, and Sanofi. Other authors have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This study has been conducted in accordance with the ethical guidelines for medical research on humans laid out in the Declaration of Helsinki. This research protocol was designed by the authors and approved by the Institutional Review Board of the National Cerebral and Cardiovascular Center and local ethics committees or local institutional review board at each study site. Although informed consent was not obtained due to the observational nature of this registry, details about the study were posted on a website and at the study sites (opt-out) to inform the subjects of the content and timeline of the study and to ensure that they have the opportunity to refuse participation in this registry. In addition, the research secretariat confirmed compliance with opt-out procedures at each study site. This study is registered with the Japanese UMIN Clinical Trials Registry (UMIN000019479).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}